Literature DB >> 32449780

Paired Basic Amino Acid-cleaving Enzyme 4 (PCSK6): An Emerging New Target Molecule in Human Melanoma.

Carsten Weishaupt1, Arianna Mastrofrancesco, Dieter Metze, Björn Kemper, Agatha Stegemann, Mauro Picardo, Andres J P Klein-Szanto, Markus Böhm.   

Abstract

Although recent therapeutic developments raise hope, melanoma remains a devastating disease with a need for new treatment targets. In other tumours prohormone convertases have been shown to be pro-tumourigenic as they are involved in processing preforms of matrix-metalloproteinases, growth factors and adhesion molecules. The aim of this study was to look for new treatment options for melanoma, by investigating the role of the prohormone convertase Paired basic Amino acid-Cleaving Enzyme 4 (PACE4/PCSK6) in melanoma cell lines and human melanoma tissue. PACE4-transfected A375 melanoma cells displayed significantly increased proliferation, MMP-2 production, gelatinase activity and migratory capacity in vitro compared with sham-transfected cells. In vivo, elevated PACE4 expression resulted in significantly increased tumour growth on immunodeficient mice. In the majority of 45 human primary melanomas and melanoma metastases ex vivo PACE4 immunoreactivity was detectable, while it was absent in in situ melanomas. These results indicate PACE4 as a regulator of melanoma cell aggressiveness.

Entities:  

Keywords:  PACE4; PCSK6; carcinogenesis; melanocytes; prohormone convertases; melanoma

Mesh:

Substances:

Year:  2020        PMID: 32449780      PMCID: PMC9137352          DOI: 10.2340/00015555-3525

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   3.875


  38 in total

1.  PACE4 expression in mouse basal keratinocytes results in basement membrane disruption and acceleration of tumor progression.

Authors:  Daniel E Bassi; Ricardo Lopez De Cicco; Jonathan Cenna; Samuel Litwin; Edna Cukierman; Andres J P Klein-Szanto
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

2.  Investigation of living pancreas tumor cells by digital holographic microscopy.

Authors:  Björn Kemper; Daniel Carl; Jürgen Schnekenburger; Ilona Bredebusch; Marcus Schäfer; Wolfram Domschke; Gert von Bally
Journal:  J Biomed Opt       Date:  2006 May-Jun       Impact factor: 3.170

3.  Proprotein convertases as therapeutic targets.

Authors:  Michel Chrétien; Nabil G Seidah; Ajoy Basak; Majambu Mbikay
Journal:  Expert Opin Ther Targets       Date:  2008-10       Impact factor: 6.902

4.  Enhanced aggressiveness of benzopyrene-induced squamous carcinomas in transgenic mice overexpressing the proprotein convertase PACE4 (PCSK6).

Authors:  Daniel E Bassi; Jonathan Cenna; Jirong Zhang; Edna Cukierman; Andres J Klein-Szanto
Journal:  Mol Carcinog       Date:  2014-05-21       Impact factor: 4.784

Review 5.  The proprotein convertases, 20 years later.

Authors:  Nabil G Seidah
Journal:  Methods Mol Biol       Date:  2011

Review 6.  The potential anti-tumorigenic and anti-metastatic side of the proprotein convertases inhibitors.

Authors:  Rachid Lahlil; Fabien Calvo; Abdel-Majid Khatib
Journal:  Recent Pat Anticancer Drug Discov       Date:  2009-01       Impact factor: 4.169

7.  Inhibition of the proprotein convertases represses the invasiveness of human primary melanoma cells with altered p53, CDKN2A and N-Ras genes.

Authors:  Claude Lalou; Nathalie Scamuffa; Samia Mourah; Francois Plassa; Marie-Pierre Podgorniak; Nadem Soufir; Nicolas Dumaz; Fabien Calvo; Nicole Basset-Seguin; Abdel-Majid Khatib
Journal:  PLoS One       Date:  2010-04-09       Impact factor: 3.240

8.  The expression of proprotein convertase PACE4 is highly regulated by Hash-2 in placenta: possible role of placenta-specific basic helix-loop-helix transcription factor, human achaete-scute homologue-2.

Authors:  Shizuyo Koide; Ichiro Yoshida; Akihiko Tsuji; Yoshiko Matsuda
Journal:  J Biochem       Date:  2003-09       Impact factor: 3.387

9.  Increased expression of the pro-protein convertase furin predicts decreased survival in ovarian cancer.

Authors:  Robert E Page; Andrés J P Klein-Szanto; Samuel Litwin; Emmanuelle Nicolas; Raid Al-Jumaily; Peter Alexander; Andrew K Godwin; Eric A Ross; Russell J Schilder; Daniel E Bassi
Journal:  Cell Oncol       Date:  2007       Impact factor: 6.730

10.  PACE4: a subtilisin-like endoprotease prevalent in the anterior pituitary and regulated by thyroid status.

Authors:  R C Johnson; D N Darlington; T A Hand; B T Bloomquist; R E Mains
Journal:  Endocrinology       Date:  1994-09       Impact factor: 4.736

View more
  1 in total

1.  AKAP12 ameliorates liver injury via targeting PI3K/AKT/PCSK6 pathway.

Authors:  Xuan Wu; Yuhong Luo; Shan Wang; Yueying Li; Meiyu Bao; Yuanjiang Shang; Lei Chen; Weiwei Liu
Journal:  Redox Biol       Date:  2022-05-06       Impact factor: 10.787

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.